1 Metabolic alterations in Crohn's disease: A Systematic Review

Atul Dev¹, Sartajdeep Kahlon¹, Jonathan Javier Ruiz¹, Avinash Chandra Kushwaha¹, Megan G.
Van Noord,² Sean H. Adams³, Kim Elaine Barrett⁴, Adam Paul Arkin⁵, Maneesh Dave^{1,6}

- 5 Author Affiliations:
- 6
- 7 ¹Division of Gastroenterology and Hepatology, Department of Internal Medicine, UC Davis
- 8 Medical Center, University of California Davis School of Medicine, Sacramento, CA, United 9 States
- ¹⁰ ²Researcher Services, University Library, University of California, Davis, Davis, CA 95616
- ³Department of Surgery and Center for Alimentary and Metabolic Science, University of
- 12 California Davis School of Medicine, Sacramento, CA, United States
- ⁴University of California Davis, School of Medicine, Sacramento, CA, United States
- ⁵Department of Bioengineering, University of California Berkeley, Berkeley, CA, United States
- 15 ⁶Department of Internal Medicine, Institute for Regenerative Cures, University of California Davis
- 16 School of Medicine, Sacramento, CA, United States
- 17

18 Correspondence:

- 19 Maneesh Dave, MD, MPH
- 20 Associate Professor of Medicine
- 21 Division of Gastroenterology and Hepatology
- 22 University of California Davis
- 23 Institute for Regenerative Cures,
- 24 Suite 1615, 2921 Stockton Blvd,
- 25 Sacramento, California 95817
- 26 Tel: 916-734-3751
- 27 Email: <u>mdave@ucdavis.edu</u>
- 28

29 Conflict of Interest Disclosures: SHA is founder and principal of XenoMed LLC, which has

- 30 interest in microbial metabolism; however, XenoMed had no role in the analyses or writing of the 31 manuscript.
- 32

Keywords: Crohn's disease; metabolomics, metabolites, bile acids, lipids and fatty acids, biogenic
 amines, gut dysbiosis.

- 35
- 36
- 37
- 38 39
- 40
- 41
- 42
- 43
- 44
- 45

46 Abstract

47

Background: Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract with an unknown etiology. Several studies have identified dysregulated metabolites in patients with CD. However, there is significant variability in the metabolites found to be dysregulated across these studies, making it unclear whether a comprehensive, disease-specific metabolic signature for CD exists.

53 **Objective**: To analyze Crohn's disease-specific metabolomic studies and available datasets to 54 identify a comprehensive signature of dysregulated metabolites and metabolic pathways 55 implicated in human CD.

56 **Design**: A comprehensive systematic review was conducted using Medline and Embase databases 57 to identify studies (from inception to May 2024) that employed analytical chemistry techniques to 58 quantify metabolites in various biological samples from Crohn's disease patients and non-IBD 59 controls. Metabolites that were significantly altered in Crohn's patients and reported in at least two 50 studies were included for further analysis.

61 **Results:** The systematic search identified 3,632 studies, with 88 selected for data extraction.
62 Across these studies, 79 metabolites were consistently reported as significantly altered in Crohn's
63 disease (CD) patients in two or more studies. These metabolites form a distinct metabolic signature
64 that differentiates CD patients from non-IBD controls, highlighting their relevance in the
65 pathophysiology of the disease.

66 **Conclusion:** This systematic review presents a comprehensive and well-defined signature of 67 dysregulated metabolites across various biological samples and provides detailed insight into the 68 perturbed metabolic pathways involved in CD.

70 **1. Introduction**

71

Inflammatory bowel disease (IBD), consisting of Crohn's disease (CD) and ulcerative colitis (UC), is a chronic relapsing-remitting inflammatory disorder of the gastrointestinal (GI) tract.[1] CD is characterized by transmural inflammation along any part of the digestive tract, which may lead to complications such as abscesses, fibrotic strictures, or fistulas.[2] The pathogenesis of CD involves epithelial barrier dysfunction, immune dysregulation, and gut dysbiosis.[3] These disruptions alter metabolic pathways, which may contribute to the initiation and/or perpetuation of chronic inflammation.[4]

79 Recent advancement of "omics" technologies has significantly enhanced our understanding of 80 Crohn's disease (CD) pathophysiology. Among these, metabolomics has emerged as a promising 81 field focused on the systematic identification and quantification of small molecules (metabolites) 82 in biological samples.[5] Each metabolite, with its unique chemistry and function, provides valuable insights into the metabolic processes occurring in the body, offering a window into the 83 84 molecular and cellular changes that distinguish healthy individuals from those with disease. 85 Current metabolomics platforms utilize both targeted and untargeted approaches, employing a 86 range of high-throughput analytical techniques to detect and characterize metabolites, providing 87 detailed information about their structure and concentration.

As CD is a complex disease, identifying dysregulated metabolites can enhance our understanding of the metabolic perturbations associated with the disease and potentially inform the development of more effective, targeted therapies. Although numerous studies have quantified and compared dysregulated metabolites in IBD patients versus non-IBD controls, significant differences exist due to differences in patient populations, disease location, biological sample types, and detection techniques. This systematic review aims to synthesize and evaluate all reported studies and

94	datasets on dysregulated metabolites in a diverse, global CD population, with the goal of
95	identifying a unique, comprehensive metabolite signature. By compiling these altered metabolites,
96	we aim to provide a detailed overview of the metabolic changes associated with CD, contributing
97	to a more precise molecular understanding of its pathophysiology.
98 99 100	2. Methods
101 102	We followed the standard PRISMA statement for performing and reporting systematic review.
103	2.1 Search strategy
104	A comprehensive literature search was conducted using the Medline and Embase databases (from
105	inception till May 2024). The search was independently performed by authors (AD, SK, JJR and
106	ACK) with the help of researcher services librarian (MGVN). Four authors (AD, SK, JJR and
107	ACK) performed initial screening of the studies and resolved any discrepancies through consensus
108	with the senior author (MD). We used free text words and MeSH terms with and without Boolean
109	operators ("AND" and "OR") to increase the sensitivity of the search (supplementary table S1).
110	The in-detailed search strategy, study inclusion and exclusion criteria, data analysis strategy are
111	available in supplementary information.

112 **3.0 Results and discussion:**

3.1 Search results: A total of 3632 studies were identified prior to excluding the duplicates [n = 91]. For initial screening, title and abstracts of 3541 studies were assessed and irrelevant studies were excluded [n = 3422] if they were not original studies or did not directly reference CD, analytical techniques, metabolomics, or metabolites. A total of 64 studies were resolved by consensus with several studies having been initially excluded by one reviewer as they only referenced UC or IBD but were eventually included as they conducted subgroup analysis of CD

119 patients. In total 119 studies were sought for full text review, among those, few studies were 120 removed [n = 31] for reasons including 'wrong indication', where studies did not include 121 metabolites, 'wrong patient population', where less than 10 CD patients were included or did not 122 utilize non-CD controls, 'wrong comparator' where comparison was not between CD patients and 123 non-IBD controls and where no analytical chemistry techniques was used to quantify the 124 metabolites. Consequently, 88 full text articles comprising in-total of 5658 CD patients and 5375 125 non-IBD controls were included as a part of the review. A PRISMA flow diagram associated with 126 this search is shown in Figure 1.

127 **3.2 Dysregulated metabolites in Crohn's disease**

Metabolites play an important role in maintaining homeostasis in the human body. Prolonged disruptions in metabolic pathways can lead to symptomatic phenotypes, with a disease-specific signatures in biological tissues, that can be quantified using metabolomic analytical techniques. (**Figure S1**). In the following paragraphs we described metabolic perturbations in CD in the four major classes.

133 **3.2.1 Lipids and Fatty acids:**

Fats, a combination of triglycerides (TGs) and fatty acids (FAs) are crucial components of cellular membranes and play vital roles in energy storage, signaling, and structural integrity of the cells. Alterations in these metabolites can disrupt biological processes, potentially leading to pathological conditions such as CD. In our systematic review, we observed SCFAs abnormalities in multiple biological samples of CD patients. Levels of butyrate/butyric acids were consistently low in the stool samples; however, no consistent pattern was observed for acetate, propionate and

140 valerate. Butyrate is synthesized via breakdown of dietary fibers by microbiota present in the colon 141 and serves as the main energy source for colonocytes, meeting approximately 70% of their daily 142 energy demand.[6, 7] CD is characterized by gut dysbiosis, with studies showing that butyrate-143 producing bacteria, such as Faecalibacterium prausnitzii and Roseburia hominis, are significantly 144 lower in CD patients, [8] and are likely responsible for the consistently low butyrate levels observed 145 in their stool samples. Butyrate maintains low oxygen levels in human colon, reduced butyric acid 146 in stool increases oxygen concentration in the lumen, and promotes aerobic bacteria overgrowth 147 further contributing to gut dysbiosis and contribute to activation of immune cells via multiple 148 inflammatory mechanism (Figure S2).[9] In an attempt to restore the lost microbial diversity of 149 butyrate producing bacteria in CD patients and to reverse mucosal inflammation, Vaughn et al.[10] 150 performed a prospective open-label study of fecal microbiota transplant (FMT) from healthy 151 controls. In this open-label study FMT was overall safe and expanded the existing microbial 152 bacterial diversity in active CD patients, although, there was variable response in clinical 153 symptoms of CD, indicating that there are multiple contributing factors which governs the disease 154 etiology. In addition to dysregulated levels of butyrate in stool, 2-hydroxybutyrate (2HB), which 155 is non-conventional form of SCFAs and considered as ketone body, showed consistent elevated 156 levels in serum samples of CD patients. Humans produce high levels of ketone bodies like 2HB 157 during increased oxidative and metabolic stress or during increased energy demand in 158 inflammatory disease like CD. Another potential reason for increased levels of 2HB in the serum 159 is the contribution from the microbial metabolism in human gut. In a recent study, Qin et al [11] 160 showed that human gut microbiota produces 2HB from methionine, threonine, aspartic acid and 161 2aminobutyric acid metabolism. In our systematic review, we observed elevated levels of 162 methionine and threonine in the biopsy samples of CD patients [12, 13] and abundance of

Bacteroidetes is well known in CD, therefore, providing a possible explanation of increased serum
 levels of 2HB in CD patients.

165 In addition to SCFAs, levels of mono-unsaturated fatty acids (MUFAs) and poly-unsaturated fatty 166 acids (PUFAs) were consistently dysregulated in serum samples of CD patients; MUFAs (Oleic 167 acid and Palmitoleic acid) were consistently elevated, while PUFAs, omega-3 fatty acids 168 (Eicosapentaenoic acid; EPA, Docosopentanoic acid; DPA, Docosahexaenoic Acid; DHA) and 169 omega-6 fatty acid (Arachidonic Acid; AA) were consistently low. Elevated levels of oleic acid, 170 palmitoleic acid, linoleic acid (LA) in serum samples of CD patients could be a sign of preferential 171 consumption of fat rich diet or presence of genetic polymorphism in genes responsible for the FAs 172 metabolism. Several studies have shown the presence of genetic polymorphism in PUFA 173 metabolism in CD.[14, 15] The FADS2 gene which catalyze the conversion of LA and ALA (Alpha 174 linolenic acid) into longer chain omega-6 and omega-3 PUFAs (EPA, DHA and AA) is often 175 dysregulated in CD.[16] In a recent study, mesenteric tissues obtained during ileocolonic resection 176 from CD patients showed decreased expression levels of FADS2 compared to the healthy 177 controls.[17] The low expression of FADS2 gene is one potential reason for the consistent low 178 levels of EPA, DHA, and AA in CD patients (Table 2) and Dietary restrictions and malabsorption 179 due to intestinal damage could further impair the intake and absorption of essential FAs required 180 for the synthesis of EPA, DPA, DHA and AA, increased demand in inflamed tissues in CD result 181 in its further depletion from the serum. Further, epidemiologic studies have linked increased intake 182 of omega-3 fatty acids with a reduced risk of CD,[18] while, increased intake of omega-6 were 183 linked to high incidence of CD.[19] [20, 21]. Omega-3 and Omega-6 fatty acids show competitive 184 binding for the same enzyme complex, and depending on preferential binding, result in a cascade 185 of pro-inflammatory or anti-inflammatory factors.[22] Therefore, a ratio of omega-3 and omega-

186 6 PUFA is considered as a more significant measure to predict the course of disease rather than 187 individual levels of omega-3 and omega-6 PUFA. A hHigher omega-3: omega-6 ratio is associated 188 with decreased susceptibility in pediatric CD.[15] Further, there was a consistent dysregulation at 189 the levels of sphingolipids and ceramides in CD patients. Sphingolipids are one of the main 190 building blocks of eukaryotic cell membranes, consisting of a sphingoid backbone that is N-191 acylated with various FAs to form several ceramide species.[23] As a class, sphingolipid and 192 ceramides were elevated in multiple biological samples in CD. However, different studies have 193 measured different sphingolipids and ceramides (varying the carbon chain length; C16, C18 etc.) 194 with little overlap in structure. Sphingolipids influence the function and trafficking of immune 195 cells by interacting with the cell surface receptors and intracellular signaling molecules. [23] 196 Ceramides, a central component of sphingolipid metabolism, can activate various stress signaling 197 pathways, to produce pro-inflammatory cytokines TNF- α and IL-1 β .[24] Furthermore, the 198 dysregulation of sphingolipid and ceramide metabolism in CD could exacerbates intestinal barrier 199 dysfunction, increasing permeability and facilitating the translocation of bacteria and other 200 antigens, which in turn perpetuates the inflammatory cycle (Figure S3). A detailed list of 201 dysregulated lipids and FAs in the biological samples from CD patients and non-IBD controls is 202 provided in Table 1.

203 **3.2.1**

Biogenic Amines and Peptides

204

A biogenic amine is a biologically synthesized molecule with one or more amine groups. Amino acids (AAs) and the proteins are some of the most common examples of biogenic amines in the human body. In our systematic review, we observed dysregulation in the serum levels of essential amino acids (EAAs) and non-essential amino acids (NEAAs) in the CD patients. Five of nine EAAs, including leucine (Leu), lysine (Lys), phenylalanine (Phe), valine (Val) and tryptophan

210 (Trp) were consistently low. Similarly, the levels of NEAAs including, tyrosine (Tyr), alanine 211 (Ala), and glutamine (Gln) followed a similar pattern in the serum and plasma samples of CD 212 patients. In contrast, elevated levels of EAAs Isoleucine (Ile) and the NEAAs Proline (Pro), 213 arginine (Arg) were observed in the serum. The low levels of EAAs could result from intestinal 214 damage caused by chronic inflammation in CD, which impairs nutrient absorption and reduces 215 their availability in serum. Abnormality in NEAAs, which are primarily synthesized by the human 216 body, indicate compromised AAs metabolism in CD patients. Additionally, active inflammation 217 leads to elevated levels of inflammatory cytokines like TNF- α , IL-6, and IL-1 β which promote 218 protein catabolism[25] to meet the increased demand for AAs by the immune cells, [26] causing 219 rapid depletion of certain preferential AAs from the serum.

220 Glutamine (Gln) and Ala are two of the most preferential fuel sources for immune cells, supporting 221 rapid proliferation and cytokine production. Additionally, gut cells utilize Gln to promote 222 enterocyte proliferation, regulate tight junctions, and protect cells from apoptosis and stress under 223 normal and pathological conditions[27]. Consistent low serum levels of Gln and Ala in CD patients 224 suggest chronic inflammation and a high immune cell demand, potentially leading to their 225 depletion in plasma and serum. [28] Interestingly, despite low serum levels, Ala was noted to be 226 highly elevated in the stool samples of CD patients. Ala is a microbial metabolite produced by 227 Proteobacteria in the human gut. A recent microbiota characterization study of IBD patients in 228 Denmark by Andersen et al [29] showed a significant increase in the *Proteobacterium* phylum in 229 CD patients, potentially explaining the elevated levels of Ala in stool samples of CD patients.

In a separate category of AAs, Leucine (Leu), and Valine (Val) known as branched chain amino acids (BCAAs), play an important role in the regular function of human immune cells and the maintenance of muscle mass.[30] These BCAAs were depleted in the serum samples of CD

patients, while levels of another BCAA isoleucine (Ile) were consistently elevated. The gut dysbiosis associated with CD can result in imbalance in the Ile metabolizing bacteria, which may lead to its preferential synthesis or poor catabolism, contributing to elevated levels in serum. While the changes in BCAAs levels have been well reported in several diseases like diabetes, however their role in CD, particularly regarding their serum and plasma levels and its clinical implications remain less clear. It is plausible that the dysregulation of BCAAs may reflect chronic inflammation, elevated mitochondrial oxidation, and altered gut microbiota.

240 Further, aromatic AAs such as Trp, Phe and Tyr levels were consistently low in the serum and 241 plasma samples of CD patients, while highly elevated in stool samples. Enterocytes absorb and 242 transport Trp via B⁰AT1 (encoded by *SLC6A19*) and TAT1 transporters (encoded by *SLC16A10*). 243 The *SLC6A19* transporter expressed primarily in small intestine, with lower levels in the colon. A 244 previous study showed SLC6A19 and SLC16A10 gene expression were significantly 245 downregulated in colon and ileal biopsies of active UC and CD patients respectively.[31] This 246 downregulation could be linked to the decreased absorption of Trp, resulting in low serum levels. 247 Consequently, reduced absorption of Trp allows excessive excretion in the stool, causing elevated 248 levels in CD patients. In addition to Trp metabolism alterations, we observed dysregulation in the 249 Tyr and Phe metabolic pathways in CD patients. The low serum levels of Phe and Tyr may be 250 attributed to the disruptions in several key metabolic pathways, including the conversion of Phe to 251 Tyr, catecholamine synthesis, and protein metabolism. Malabsorption may further contribute to 252 their poor absorption and increased stool levels, while increased metabolic demands in CD could 253 reduce Phe levels, subsequently leading to decreased Tyr levels in the serum. [32, 33] In addition 254 to aromatic AAs, levels of creatine, an endogenous AA, are significantly elevated in the serum and 255 plasma samples of CD patients compared to non-IBD controls. Human body synthesizes creatine

from methionine, arginine, and glycine and uses it as an energy source for muscles. Higher serum creatine levels indicate increased energy requirement in the muscles due to metabolic stress and inflammation. Other AAs, such as methionine, histidine, aspartic acid, arginine, ornithine, were also dysregulated in CD patients; however, we did not find any consistent trend in their dysregulation. A complete list of dysregulated biogenic amines and AAs in biological samples from CD patients and non-IBD controls is provided in **Table 2**.

262

263 3.2.2 Bile acid and bile salts

264

265 Bile acids (BAs) are essential components of bile and crucial for the emulsification and absorption 266 of dietary fats and fat-soluble vitamins. BAs are synthesized in the liver from cholesterol and are 267 termed as primary BAs (cholic acid; CA and chenodeoxycholic acid; CDCA). The human body 268 maintains a pool of BAs in enterohepatic circulation, which is primarily (>90%) composed of 269 conjugated CA, CDCA and deoxycholic acid (DCA); with lithocholic acid (LCA), and 270 ursodeoxycholic acid (UDCA) present in traces amount. Approximately 95% of intestinal BAs are 271 reabsorbed in the terminal ileum via the apical sodium-dependent bile acid transporter (ASBT) 272 and by passive diffusion into the hepatic portal vein, with residual $\sim 5\%$ BAs pool excreted through 273 the feces.[34] The gut microbiota plays a central role in the maintaining the of BAs pool through 274 enzymatic deconjugation and dehydroxylation reactions, producing unconjugated primary and 275 secondary BAs. The gut microbiome deconjugates primary BAs via bile salt hydrolase (BSH); 276 while $7\alpha/\beta$ -dehydroxylases and hydroxysteroid dehydrogenases (HSDHs) are responsible for 277 dehydroxylation and epimerization into secondary BAs.[35] Bacteroides spp. play a major role in 278 deconjugation of primary BAs, while *Firmicutes* are responsible for the $7\alpha/\beta$ -dehydroxylation.[36] 279 Gut dysbiosis, common in CD, is characterized by an abundance of *Bacteroides* [4, 37] and loss

in diversity of *Firmicutes*.[38] Dysregulation of these microbiota strongly affects the BAs
homeostasis in human gut, resulting in altered BAs profile (low serum levels of Taurocholic acid;
TCA, Glycholic acid; GCA, Taurochenodeoxycholic acid; TCDCA, Glycochenodeoxycholic acid;
GCDCA, Taurodeoxycholic acid;TDCA, Glycodeoxycholic acid; GDCA, Glycolithocholic acid;
GLCA, Tauroursodeoxycholic acid; TUDCA) and low stool levels of DCA, LCA, and UDCA
and BA induced diarrhea in CD patients. A significant percentage of CD patients undergo small
bowel resection, which further decreases reabsorption of BAs resulting in deficiency of BAs in

287

CD patients.[39]

288 In addition to the fat absorption, BAs play important role in immune regulation in human body. 289 BAs modulate the systemic pro-inflammatory/anti-inflammatory balance by binding to farnesoid 290 X receptor (FXR), Takeda G protein-coupled receptor 5 (TGR5), and other non-canonical BAs 291 receptors (Figure S4).[40, 41] FXR is a nuclear transcription factor and highly expressed in the 292 human gut, liver and innate immune cells such as macrophages.[42] FXR activation in myeloid 293 cells suppresses intestinal inflammation by inhibiting NF-kB/NLRP3-induced expression of 294 TNFα, IL-1β, and IL-6.[43] In addition to FXR, TGR5 plays an important role in BAs homeostasis 295 and shaping intestinal immunity. TGR5 is a G-protein coupled receptor present in the cell 296 membranes and is widely expressed in small intestine, colon, adipocytes, and innate immune 297 cells.[44] TGR5 signaling has an anti-inflammatory effect and prevents the production of pro-298 inflammatory cytokines TNF α and IL-1 β ,[45] highlighting the importance of TGR-5 signaling in 299 CD. BAs dysregulation can be attributed to gut dysbiosis in CD, and correcting gut dysbiosis 300 represents a potential therapeutic approach for the treatment of CD. In a recent study, Zhou et al. 301 showed that oral gavage treatment with a BAs consortium (BAC; *Clostridium AP sp000509125*, 302 Bacteroides ovatus, and Eubacterium limosum) in mice had protective effects against DSS-

induced colitis, suggesting that a rationally designed bacterial consortium could reshape gut microbiome metabolism to treat CD.[46] A complete list of dysregulated BAs and bile salts in biological samples from CD patients and non-IBD controls is provided in **Table 3**.

306 307

3.2.3 Other primary metabolites

308 In our systematic review, we observed reduced levels of alpha-ketoglutarate (AKG), succinate, 309 and citrate in the serum and urine samples of CD patients. These metabolites are key intermediates 310 of the TCA cycle, and their dysregulation suggests impaired mitochondrial metabolic pathways. 311 The human body tightly regulates citrate availability and elimination from the body based upon 312 the nutritional intake, cellular metabolism, renal clearance, and bone remodeling. Consistently low 313 levels of citrate in the urine samples of CD patients may be linked to poor absorption from the diet 314 or increased cellular metabolism. CD is characterized by chronic inflammation with increased 315 numbers and activity of immune cells and increased energy demand. To meet these energy 316 requirements, immune cell metabolism shifts towards glycolysis, leading to a compromised TCA 317 cycle. Activated macrophages exhibit a disrupted TCA cycle with reduced isocitrate 318 dehydrogenase (IDH) activity. IDH normally converts citrate to AKG, but its low expression in 319 activated macrophages leads to citrate accumulation in the immune cells and decreased AKG 320 production. Immune cells import citrate both extracellularly and intracellularly to meet their 321 increased energy demands. Accumulated citrate is then metabolized to several intermediates that 322 contribute to the production of pro-inflammatory molecules.[47] Inflammatory environment in 323 CD increase the demand for citrate in the serum to fuel immune cells, resulting in the low levels 324 in urine samples. In addition to citrate, succinate, another metabolite of TCA cycle, is implicated 325 in CD. Succinate shows similarly dysregulated pattern in CD patients compared to non-IBD 326 controls, potentially indicating shared dysregulated pathways. Elevated levels of intracellular and

327 extracellular succinate are pro-inflammatory, contributing to activation and maintenance of the 328 pro-inflammatory state of macrophages during inflammation. Besides, the TCA cycle 329 intermediates, we also observed consistently low levels of hippurate in the urine samples of CD 330 patients. Urinary hippurate is a product of the microbial metabolism of certain dietary compounds, 331 such as benzoic acid, and p-cresol sulphate (a metabolite of *Clostridia* spp. metabolism of 332 tyrosine). In CD, the reduction in Clostridium cluster IV and Faecalibacterium prausnitzii has 333 been linked to low levels of hippurate, Schicho et al. [48] reported significantly reduced levels of 334 p-cresol in the urine of CD patients compared to healthy subjects, indicating potential dysbiosis 335 of *Clostridia spp* in CD, which may contribute to the reduced levels of hippurate levels.

336 In addition to hippurate, several volatile metabolites produced by microbial metabolism and 337 oxidative stress were implicated in CD patients. We detected dysregulated levels of acetate, 338 ethanol, isoprene, pentane, acetone and butanoic acid in breath samples of CD patients compared 339 to non-IBD controls. However, most of these metabolites, except pentane, did not show a 340 consistent pattern in CD. Pentane levels were consistently elevated in breath samples of CD 341 patients, likely as a result of lipid peroxidation due to oxidative stress.[49] CD is characterized by 342 elevated levels of reactive oxygen species and disruptions in lipid metabolism, which may 343 contribute to the increased pentane levels in breath samples. A complete list of other dysregulated 344 primary metabolites in biological samples from CD patients and non-IBD controls is provided in 345 Table 4.

346

347 **4.** Conclusion

A key takeaway from the systematic review and analyses is that dysregulated metabolites in CD
patients compared to non-CD controls, span multiple metabolite classes, including lipids and fatty

350 acids, biogenic amines and peptides, bile acids and bile salts, as well as other primary metabolites. 351 Each category of metabolite provides a distinct signature within the biological samples of CD 352 patients. Notably, certain key metabolites such as butyrate, 2HB, Ile, Ala, primary and secondary 353 BAs, and hippurate, were strongly influenced by the gut dysbiosis linked to the CD. However, it 354 remains unclear whether these dysregulated metabolites are a cause or a consequence of gut 355 dysbiosis in CD. Another strength of our systematic review lies in the comprehensive comparison 356 of individual metabolites between CD patients and non-IBD controls. The metabolites reported 357 were not only consistently identified across multiple studies but were also detected using diverse, 358 high-throughput analytical techniques across various biological sample types, adding robustness 359 to our findings. This study's limitations include the focus on metabolites identified in at least two 360 independent studies, which may have excluded CD-associated metabolites found in single studies 361 due to differing analytical libraries and resources. Despite this, the metabolites presented are robust 362 and provide a foundation for further exploration of their roles in the CD phenotype. Additionally, 363 variability in disease severity, inflammation sites, and medical therapeutics, may have influenced 364 metabolite detection, as many studies did not stratify subjects based on disease severity. Future 365 research is required to distinguish cause from effect in CD-associated metabolites and examine 366 how CD progression interacts with host and microbial metabolism. Additionally, the limited 367 publicly available data restricts comprehensive analyses, and more data in standardized 368 repositories would enable better assessment and validation of metabolic signatures in Crohn's 369 disease. Our systematic review identified a comprehensive profile of metabolites that are important 370 in pathophysiology of Crohn's disease.

371 Author Contributions:

372 AD, SK, JJR and ACK independently searched studies with the help of MGVN, who helped as a

373 systematic review librarian in retrieving the studies. AD and SK independently extracted the data

374 from the studies. AD performed data analysis and wrote the manuscript with the help of JJR, ACK

and MD. SHA, and APA served as peer reviewers and experts in the field to contribute edits and

- 376 suggestions throughout the writing process. MD conceptualized and designed the study and
- 377 provided supervision.

378 Acknowledgments:

- 379 This work was supported by UC Davis School of Medicine TriP program (MD and APA). The
- 380 funding agencies had no role in the study analysis or writing of the manuscript. Its contents are
- 381 solely the responsibility of the authors.

382 **References:**

Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic
 review. Gut 2012;61:1619-35.

2 Chang JT. Pathophysiology of Inflammatory Bowel Diseases. N Engl J Med
 2020;383:2652-64.

387 3 Dave M, Papadakis KA, Faubion WA, Jr. Immunology of inflammatory bowel disease and 388 molecular targets for biologics. Gastroenterol Clin North Am 2014;**43**:405-24.

389 4 Imhann F, Vich Vila A, Bonder MJ, Fu J, Gevers D, Visschedijk MC, *et al.* Interplay of 390 host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory

391 bowel disease. Gut 2018;**67**:108-19.

392 5 Nicholson JK, Lindon JC. Systems biology: Metabonomics. Nature 2008;455:1054-6.

Macfarlane GT, Macfarlane S. Fermentation in the human large intestine: its physiologic
 consequences and the potential contribution of prebiotics. J Clin Gastroenterol 2011;45
 Suppl:S120-7.

Goncalves P, Martel F. Butyrate and colorectal cancer: the role of butyrate transport. Curr
 Drug Metab 2013;14:994-1008.

398 8 Cao Y, Shen J, Ran ZH. Association between Faecalibacterium prausnitzii Reduction and
399 Inflammatory Bowel Disease: A Meta-Analysis and Systematic Review of the Literature.
400 Gastroenterol Res Pract 2014;2014:872725.

401 9 Siddiqui MT, Cresci GAM. The Immunomodulatory Functions of Butyrate. J Inflamm Res
 402 2021;14:6025-41.

Vaughn BP, Vatanen T, Allegretti JR, Bai A, Xavier RJ, Korzenik J, *et al.* Increased
Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohn's Disease.
Inflamm Bowel Dis 2016;22:2182-90.

406 11 Qin F, Li J, Mao T, Feng S, Li J, Lai M. 2 Hydroxybutyric Acid-Producing Bacteria in Gut
407 Microbiome and Fusobacterium nucleatum Regulates 2 Hydroxybutyric Acid Level In Vivo.
408 Metabolites 2023;13.

409 12 Adegbola SO, Sarafian M, Sahnan K, Ding NS, Faiz OD, Warusavitarne J, et al. 410 Differences amino acid and lipid metabolism distinguish Crohn's in from 411 idiopathic/cryptoglandular perianal fistulas by tissue metabonomic profiling and may offer clues 412 to underlying pathogenesis. Eur J Gastroenterol Hepatol 2021;33:1469-79.

- 13 Nystrom N, Prast-Nielsen S, Correia M, Globisch D, Engstrand L, Schuppe-Koistinen I, *et*414 *al.* Mucosal and Plasma Metabolomes in New-onset Paediatric Inflammatory Bowel Disease:
 415 Correlations with Disease Characteristics and Plasma Inflammation Protein Markers. J Crohns
 416 Colitis 2023;17:418-32.
- 417 14 Costea I, Mack DR, Israel D, Morgan K, Krupoves A, Seidman E, *et al.* Genes involved in
 418 the metabolism of poly-unsaturated fatty-acids (PUFA) and risk for Crohn's disease in children &
 419 young adults. PLoS One 2010;5:e15672.
- Lemaitre RN, Israel D, Marcil V, Ahmad A, *et al.* Interactions between
 the dietary polyunsaturated fatty acid ratio and genetic factors determine susceptibility to pediatric
 Crohn's disease. Gastroenterology 2014;**146**:929-31.
- Lattka E, Illig T, Heinrich J, Koletzko B. Do FADS genotypes enhance our knowledge
 about fatty acid related phenotypes? Clin Nutr 2010;29:277-87.
- Liu R, Qiao S, Shen W, Liu Y, Lu Y, Liangyu H, *et al.* Disturbance of Fatty Acid
 Desaturation Mediated by FADS2 in Mesenteric Adipocytes Contributes to Chronic Inflammation
 of Crohn's Disease. J Crohns Colitis 2020;14:1581-99.
- 428 18 Chan SS, Luben R, Olsen A, Tjonneland A, Kaaks R, Lindgren S, *et al.* Association 429 between high dietary intake of the n-3 polyunsaturated fatty acid docosahexaenoic acid and 430 reduced risk of Crohn's disease. Aliment Pharmacol Ther 2014;**39**:834-42.
- 431 19 Shoda R, Matsueda K, Yamato S, Umeda N. Epidemiologic analysis of Crohn disease in
 432 Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the
 433 increased incidence of Crohn disease in Japan. Am J Clin Nutr 1996;63:741-5.
- 434 20 Peters V, Bolte L, Schuttert EM, Andreu-Sanchez S, Dijkstra G, Weersma RK, *et al.* 435 Western and Carnivorous Dietary Patterns are Associated with Greater Likelihood of IBD
- 436 Development in a Large Prospective Population-based Cohort. J Crohns Colitis 2022;**16**:931-9.
- 437 21 Li T, Qiu Y, Yang HS, Li MY, Zhuang XJ, Zhang SH, *et al.* Systematic review and meta-438 analysis: Association of a pre-illness Western dietary pattern with the risk of developing 439 inflammatory bowel disease. J Dig Dis 2020;**21**:362-71.
- Lands B, Bibus D, Stark KD. Dynamic interactions of n-3 and n-6 fatty acid nutrients.
 Prostaglandins Leukot Essent Fatty Acids 2018;136:15-21.
- 442 23 Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature 443 2014;**510**:58-67.
- 444 24 Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from 445 sphingolipids. Nat Rev Mol Cell Biol 2008;**9**:139-50.
- 446 25 Spate U, Schulze PC. Proinflammatory cytokines and skeletal muscle. Curr Opin Clin Nutr
- 447 Metab Care 2004;7:265-9.

- 448 26 Yang L, Chu Z, Liu M, Zou Q, Li J, Liu Q, et al. Amino acid metabolism in immune cells:
- essential regulators of the effector functions, and promising opportunities to enhance cancerimmunotherapy. J Hematol Oncol 2023;16:59.
- 451 27 Kim MH, Kim H. The Roles of Glutamine in the Intestine and Its Implication in Intestinal
 452 Diseases. Int J Mol Sci 2017;18.
- 453 28 Felig P, Pozefsky T, Marliss E, Cahill GF, Jr. Alanine: key role in gluconeogenesis.
 454 Science 1970;167:1003-4.
- 455 29 Vester-Andersen MK, Mirsepasi-Lauridsen HC, Prosberg MV, Mortensen CO, Trager C,
- 456 Skovsen K, *et al.* Increased abundance of proteobacteria in aggressive Crohn's disease seven years 457 after diagnosis. Sci Rep 2019;**9**:13473.
- 458 30 Hey P, Gow P, Testro AG, Apostolov R, Chapman B, Sinclair M. Nutraceuticals for the 459 treatment of sarcopenia in chronic liver disease. Clin Nutr ESPEN 2021;**41**:13-22.
- 460 31 Wang S, van Schooten FJ, Jin H, Jonkers D, Godschalk R. The Involvement of Intestinal 461 Tryptophan Metabolism in Inflammatory Bowel Disease Identified by a Meta-Analysis of the 462 Transactintoma and a Surtematic Parian of the Matcheleme Nutrients 2022:15
- 462 Transcriptome and a Systematic Review of the Metabolome. Nutrients 2023;**15**.
- 463 32 Fernstrom JD, Fernstrom MH. Tyrosine, phenylalanine, and catecholamine synthesis and
 464 function in the brain. J Nutr 2007;137:1539S-47S; discussion 48S.
- 465 33 Flydal MI, Martinez A. Phenylalanine hydroxylase: function, structure, and regulation.
 466 IUBMB Life 2013;65:341-9.
- 467 34 Fleishman JS, Kumar S. Bile acid metabolism and signaling in health and disease:
 468 molecular mechanisms and therapeutic targets. Signal Transduct Target Ther 2024;9:97.
- 469 35 Di Ciaula A, Garruti G, Lunardi Baccetto R, Molina-Molina E, Bonfrate L, Wang DQ, et
 470 al. Bile Acid Physiology. Ann Hepatol 2017;16:s4-s14.
- 471 36 Ovadia C, Perdones-Montero A, Spagou K, Smith A, Sarafian MH, Gomez-Romero M, *et*472 *al.* Enhanced Microbial Bile Acid Deconjugation and Impaired Ileal Uptake in Pregnancy Repress
 473 Intestinal Regulation of Bile Acid Synthesis. Hepatology 2019;**70**:276-93.
- 37 Becker HEF, Jamin C, Bervoets L, Boleij A, Xu P, Pierik MJ, *et al.* Higher Prevalence of
 Bacteroides fragilis in Crohn's Disease Exacerbations and Strain-Dependent Increase of Epithelial
 Resistance. Front Microbiol 2021;12:598232.
- 477 38 Kowalska-Duplaga K, Gosiewski T, Kapusta P, Sroka-Oleksiak A, Wedrychowicz A,
 478 Pieczarkowski S, *et al.* Differences in the intestinal microbiome of healthy children and patients
 479 with newly diagnosed Crohn's disease. Sci Rep 2019;9:18880.
- 480 39 Hojo A, Kobayashi T, Matsubayashi M, Morikubo H, Miyatani Y, Fukuda T, *et al.*481 Usefulness of colestimide for diarrhea in postoperative Crohn's disease. JGH Open 2022;6:547482 53.
- 483 40 Choudhuri S, Klaassen CD. Molecular Regulation of Bile Acid Homeostasis. Drug Metab
 484 Dispos 2022;**50**:425-55.
- 485 41 Chiang JY. Bile acid metabolism and signaling. Compr Physiol 2013;**3**:1191-212.
- 486 42 Wang YD, Chen WD, Moore DD, Huang W. FXR: a metabolic regulator and cell protector.
 487 Cell Res 2008;18:1087-95.
- 43 Anderson KM, Gayer CP. The Pathophysiology of Farnesoid X Receptor (FXR) in the GI
 489 Tract: Inflammation, Barrier Function and Innate Immunity. Cells 2021;10.
- 490 44 Chiang JY, Pathak P, Liu H, Donepudi A, Ferrell J, Boehme S. Intestinal Farnesoid X
- 491 Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation. Dig Dis
- 492 2017;**35**:241-5.

493 45 Yoneno K, Hisamatsu T, Shimamura K, Kamada N, Ichikawa R, Kitazume MT, *et al.*494 TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated
495 inflammatory and intestinal macrophages in Crohn's disease. Immunology 2013;139:19-29.

496 46 Zhou C, Wang Y, Li C, Xie Z, Dai L. Amelioration of Colitis by a Gut Bacterial
497 Consortium Producing Anti-Inflammatory Secondary Bile Acids. Microbiol Spectr
498 2023;11:e0333022.

- 47 Jha AK, Huang SC, Sergushichev A, Lampropoulou V, Ivanova Y, Loginicheva E, *et al.*500 Network integration of parallel metabolic and transcriptional data reveals metabolic modules that
 regulate macrophage polarization. Immunity 2015;42:419-30.
- 502 48 Schicho R, Shaykhutdinov R, Ngo J, Nazyrova A, Schneider C, Panaccione R, *et al.* 503 Quantitative metabolomic profiling of serum, plasma, and urine by (1)H NMR spectroscopy 504 discriminates between patients with inflammatory bowel disease and healthy individuals. J 505 Proteome Res 2012;**11**:3344-57.
- 506 49 Yoshida Y, Umeno A, Shichiri M. Lipid peroxidation biomarkers for evaluating oxidative 507 stress and assessing antioxidant capacity in vivo. J Clin Biochem Nutr 2013;**52**:9-16.
- 508 50 Vancamelbeke M, Sabino, J., Deroover, L., Vandermeulen, G., Luypaerts, A., Ferrante, 509 M., Falony, G., Vieira-Silva, S., Verbeke, K., Raes, J., Cleynen, I., & Vermeire, S. Tu1862-510 Profiling of the fecal microbiota and metabolome in patients with inflammatory bowel disease and 511 their unaffected relatives. Gastroenterology 2017:S991.
- 512 51 Dryahina K, Smith D, Bortlik M, Machkova N, Lukas M, Spanel P. Pentane and other 513 volatile organic compounds, including carboxylic acids, in the exhaled breath of patients with 514 Crohn's disease and ulcerative colitis. J Breath Res 2017;**12**:016002.
- 515 52 Zhgun ES, Kislun YV, Kalachniuk TN, Veselovsky VA, Urban AS, Tikhonova PO, *et al.*516 [Evaluation of metabolites levels in feces of patients with inflammatory bowel diseases]. Biomed
 517 Khim 2020;66:233-40.
- 518 53 Marchesi JR, Holmes E, Khan F, Kochhar S, Scanlan P, Shanahan F, *et al.* Rapid and 519 noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 520 2007;**6**:546-51.
- 521 54 Alonso A, Julia A, Vinaixa M, Domenech E, Fernandez-Nebro A, Canete JD, *et al.* Urine 522 metabolome profiling of immune-mediated inflammatory diseases. BMC Med 2016;**14**:133.
- 523 55 Bjerrum JT, Wang Y, Hao F, Coskun M, Ludwig C, Gunther U, *et al.* Metabonomics of 524 human fecal extracts characterize ulcerative colitis, Crohn's disease and healthy individuals. 525 Metabolomics 2015;**11**:122-33.
- 526 56 Hu J, Cheng S, Yao J, Lin X, Li Y, Wang W, *et al.* Correlation between altered gut 527 microbiota and elevated inflammation markers in patients with Crohn's disease. Front Immunol 528 2022;**13**:947313.
- 529 57 Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, *et* 530 *al.* Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature
- 531 2019;**569**:655-62.
- 532 58 Ambrozkiewicz F, Karczmarski J, Kulecka M, Paziewska A, Niemira M, Zeber-Lubecka 533 N, *et al.* In search for interplay between stool microRNAs, microbiota and short chain fatty acids 534 in Crohn's disease - a preliminary study. BMC Gastroenterol 2020;**20**:307.
- 535 59 Walton C, Fowler DP, Turner C, Jia W, Whitehead RN, Griffiths L, et al. Analysis of
- volatile organic compounds of bacterial origin in chronic gastrointestinal diseases. Inflamm Bowel
- 537 Dis 2013;**19**:2069-78.

538 60 De Preter V, Machiels K, Joossens M, Arijs I, Matthys C, Vermeire S, *et al.* Faecal 539 metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD. Gut 540 2015;**64**:447-58.

541 61 Aldars-Garcia L, Gil-Redondo R, Embade N, Riestra S, Rivero M, Gutierrez A, *et al.*542 Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naive Inflammatory
543 Bowel Disease Patients. Inflamm Bowel Dis 2024;**30**:167-82.

544 62 Murgia A, Hinz C, Liggi S, Denes J, Hall Z, West J, *et al.* Italian cohort of patients affected 545 by inflammatory bowel disease is characterised by variation in glycerophospholipid, free fatty 546 acids and amino acid levels. Metabolomics 2018;**14**:140.

- 547 63 Di Giovanni N, Meuwis MA, Louis E, Focant JF. Untargeted Serum Metabolic Profiling
 548 by Comprehensive Two-Dimensional Gas Chromatography-High-Resolution Time-of-Flight
 549 Mass Spectrometry. J Proteome Res 2020;19:1013-28.
- 550 64 Esteve-Comas M, Ramirez M, Fernandez-Banares F, Abad-Lacruz A, Gil A, Cabre E, *et* 551 *al.* Plasma polyunsaturated fatty acid pattern in active inflammatory bowel disease. Gut 552 1992;**33**:1365-9.
- 553 65 Figler M, Gasztonyi B, Cseh J, Horvath G, Kisbenedek AG, Bokor S, *et al.* Association of 554 n-3 and n-6 long-chain polyunsaturated fatty acids in plasma lipid classes with inflammatory bowel 555 diseases. Br J Nutr 2007;**97**:1154-61.
- 556 66 Jansson J, Willing B, Lucio M, Fekete A, Dicksved J, Halfvarson J, *et al.* Metabolomics 557 reveals metabolic biomarkers of Crohn's disease. PLoS One 2009;4:e6386.
- 558 67 Kuroki F, Iida M, Matsumoto T, Aoyagi K, Kanamoto K, Fujishima M. Serum n3 559 polyunsaturated fatty acids are depleted in Crohn's disease. Dig Dis Sci 1997;**42**:1137-41.
- 560 68 Geerling BJ, v Houwelingen AC, Badart-Smook A, Stockbrugger RW, Brummer RJ. Fat 561 intake and fatty acid profile in plasma phospholipids and adipose tissue in patients with Crohn's 562 disease, compared with controls. Am J Gastroenterol 1999;**94**:410-7.
- 563 69 Jiang J, Chen L, Sun R, Yu T, Jiang S, Chen H. Characterization of serum polyunsaturated 564 fatty acid profile in patients with inflammatory bowel disease. Ther Adv Chronic Dis 565 2023;14:20406223231156826.
- 566 70 Scoville EA, Allaman MM, Adams DW, Motley AK, Peyton SC, Ferguson SL, *et al.* 567 Serum Polyunsaturated Fatty Acids Correlate with Serum Cytokines and Clinical Disease Activity 568 in Crohn's Disease. Sci Rep 2019;**9**:2882.
- 569 71 Akazawa Y, Morisaki T, Fukuda H, Norimatsu K, Shiota J, Hashiguchi K, *et al.* 570 Significance of serum palmitoleic acid levels in inflammatory bowel disease. Sci Rep 571 2021;**11**:16260.
- 572 72 Kruchinina MV, Gromov, A. A., Svetlova, I. O., Azgaldyan, A. V., Kruchinin, V. N.,
 573 Shashkov, M. V., & Sokolova, A. S. P0388-New diagnostic capabilities for crohn's disease: Use
 574 of fatty acid profiles of erythrocyte membranes and blood serum. United European
 575 Gastroenterology Journal 2020 334-5.
- 576 73 Ben-Mustapha Y, Ben-Fradj MK, Hadj-Taieb S, Serghini M, Ben Ahmed M, Boubaker J, 577 *et al.* Altered mucosal and plasma polyunsaturated fatty acids, oxylipins, and endocannabinoids
- 578 profiles in Crohn's disease. Prostaglandins Other Lipid Mediat 2023;**168**:106741.
- 579 74 Lai Y, Xue J, Liu CW, Gao B, Chi L, Tu P, *et al.* Serum Metabolomics Identifies Altered
 580 Bioenergetics, Signaling Cascades in Parallel with Exposome Markers in Crohn's Disease.
 581 Molecules 2019;24.

582 75 Levy E, Rizwan Y, Thibault L, Lepage G, Brunet S, Bouthillier L, *et al.* Altered lipid
583 profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am
584 J Clin Nutr 2000;71:807-15.

585 76 Alghamdi A, Gerasimidis K, Blackburn G, Akinci D, Edwards C, Russell RK, *et al.*586 Untargeted Metabolomics of Extracts from Faecal Samples Demonstrates Distinct Differences
587 between Paediatric Crohn's Disease Patients and Healthy Controls but No Significant Changes
588 Resulting from Exclusive Enteral Nutrition Treatment. Metabolites 2018;8.

- 589 77 Fathi F, Majari-Kasmaee L, Mani-Varnosfaderani A, Kyani A, Rostami-Nejad M, 590 Sohrabzadeh K, *et al.* 1H NMR based metabolic profiling in Crohn's disease by random forest 591 methodology. Magn Reson Chem 2014;**52**:370-6.
- 592 78 Kruchinina MV, Gromov, A. A., Svetlova, I. O., Azgaldyan, A. V., Kruchinin, V. N.,
 593 Shashkov, M. V., Sokolova, A. S., Yakovina, I. N., & Shestov, A. A. P0305-Peculiarities of fatty
 594 acid profiles of erythrocyte membranes and blood serum depending on activity rate of Crohn's
 595 disease. United European Gastroenterology Journal 2021:436.
- 596 79 Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, *et al.* 597 Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol 598 2019;4:293-305.
- 599 80 Chen B, Wang Y, Wang Q, Li D, Huang X, Kuang X, *et al.* Untargeted metabolomics 600 identifies potential serum biomarkers associated with Crohn's disease. Clin Exp Med 601 2023;**23**:1751-61.
- 81 Filimoniuk A, Blachnio-Zabielska A, Imierska M, Lebensztejn DM, Daniluk U.
 Sphingolipid Analysis Indicate Lactosylceramide as a Potential Biomarker of Inflammatory Bowel
 Disease in Children. Biomolecules 2020;10.
- 605 82 Braun A, Treede I, Gotthardt D, Tietje A, Zahn A, Ruhwald R, *et al.* Alterations of 606 phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative 607 colitis: a clue to pathogenesis. Inflamm Bowel Dis 2009;**15**:1705-20.
- 608 83 Ferru-Clement R, Boucher G, Forest A, Bouchard B, Bitton A, Lesage S, *et al.* Serum
 609 Lipidomic Screen Identifies Key Metabolites, Pathways, and Disease Classifiers in Crohn's
 610 Disease. Inflamm Bowel Dis 2023;29:1024-37.
- 611 84 Fan F, Mundra PA, Fang L, Galvin A, Moore XL, Weir JM, *et al.* Lipidomic Profiling in
 612 Inflammatory Bowel Disease: Comparison Between Ulcerative Colitis and Crohn's Disease.
 613 Inflamm Bowel Dis 2015;21:1511-8.
- 614 85 Iwatani S, Iijima H, Otake Y, Amano T, Tani M, Yoshihara T, *et al.* Novel mass
- spectrometry-based comprehensive lipidomic analysis of plasma from patients with inflammatory
 bowel disease. J Gastroenterol Hepatol 2020;35:1355-64.
- 617 86 Kurada S, Grove, D., Mao, R., Singh, A., Sarvepalli, S., Lopez, R., Fiocchi, C., Rogler, G.,
- 618 Kunst, C., Dweik, R., & Rieder, F. . Sa1789-Serum headspace metabolome analysis discriminates
- 619 crohn's disease from controls with high accuracy and is linked to disease phenotypes.620 Gastroenterology 2018 S-395.
- 87 Williams HR, Willsmore JD, Cox IJ, Walker DG, Cobbold JF, Taylor-Robinson SD, *et al.*622 Serum metabolic profiling in inflammatory bowel disease. Dig Dis Sci 2012;**57**:2157-65.
- 623 88 Jagt JZ, Struys EA, Ayada I, Bakkali A, Jansen EEW, Claesen J, et al. Fecal Amino Acid
- 624 Analysis in Newly Diagnosed Pediatric Inflammatory Bowel Disease: A Multicenter Case-Control
- 625 Study. Inflamm Bowel Dis 2022;**28**:755-63.

89 Powles STR, Gallagher, K., Hicks, L. C., Chong, L. W., Swann, J. R., Holmes, E.,
Williams, H. R. T., & Orchard, T. R. PTH-112 Effect of co-morbidities in crohn's disease
associated urinary metabolic profiles. Gut 2019:A89-A90.

- 629 90 Lins Neto MAF, Verdi GMX, Veras AO, Veras MO, Caetano LC, Ursulino JS. Use of
 630 Metabolomics to the Diagnosis of Inflammatory Bowel Disease. Arq Gastroenterol 2020;57:311631 5.
- 632 91 Ooi M, Nishiumi S, Yoshie T, Shiomi Y, Kohashi M, Fukunaga K, et al. GC/MS-based
- 633 profiling of amino acids and TCA cycle-related molecules in ulcerative colitis. Inflamm Res
- 634 2011;**60**:831-40.
- 635 92 Scoville EA, Allaman MM, Brown CT, Motley AK, Horst SN, Williams CS, *et al.*636 Alterations in Lipid, Amino Acid, and Energy Metabolism Distinguish Crohn's Disease from
 637 Ulcerative Colitis and Control Subjects by Serum Metabolomic Profiling. Metabolomics
 638 2018;14:17.
- 639 93 Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V. Faecal and Serum
 640 Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis 2017;11:321-34.
- 641 94 Krzystek-Korpacka M, Fleszar MG, Bednarz-Misa I, Lewandowski L, Szczuka I, 642 Kempinski R, *et al.* Transcriptional and Metabolomic Analysis of L-Arginine/Nitric Oxide 643 Pathway in Inflammatory Bowel Disease and Its Association with Local Inflammatory and 644 Angiogenic Response: Preliminary Findings. Int J Mol Sci 2020;**21**.
- 645 95 Owczarek D, Cibor D, Mach T. Asymmetric dimethylarginine (ADMA), symmetric 646 dimethylarginine (SDMA), arginine, and 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha) level in 647 patients with inflammatory bowel diseases. Inflamm Bowel Dis 2010;**16**:52-7.
- Herlekar D, Martin, F. P., Zhang, S., Bosworth, B., Montoliu, I., Collino, S., Yantiss, R.,
 Kochnar, S., Scherl, E., Dogan, B., & Simpson, K. Chemical perturbations in the inflamed ileum
 promote the growth of crohn's associated adherent and invasive E. coli. Inflammatory Bowel
 Diseases 2013:S121.
- 652 97 Tews HC, Schmelter F, Kandulski A, Buchler C, Schmid S, Schlosser S, *et al.* Unique
 653 Metabolomic and Lipidomic Profile in Serum From Patients With Crohn's Disease and Ulcerative
 654 Colitis Compared With Healthy Control Individuals. Inflamm Bowel Dis 2023.
- 655 98 Williams HR, Cox IJ, Walker DG, North BV, Patel VM, Marshall SE, *et al.* 656 Characterization of inflammatory bowel disease with urinary metabolic profiling. Am J 657 Gastroenterol 2009;**104**:1435-44.
- 658 99 Bosch S, Struys EA, van Gaal N, Bakkali A, Jansen EW, Diederen K, *et al.* Fecal Amino
- Acid Analysis Can Discriminate De Novo Treatment-Naive Pediatric Inflammatory Bowel
 Disease From Controls. J Pediatr Gastroenterol Nutr 2018;66:773-8.
- 661 100 Levhar N, Hadar, R., Braun, T., Efroni, G., Abramovich, I., Gottlieb, E., Sosnovski, K.,
- Abass, H., Berger, T., Granot, M., Neuman, S., Selinger Feigin, L., Picard, O., Yavzuri, M., Lahat,
 A., Eliakim, A., Weiss, B., Kopylov, U., Ben-Horin, S., Amir, A., Haberman, Y. P0239-
- 664 Untargeted serum metabolome in longitudinal Crohn's disease (CD) cohort enrolled during
- 665 remission shows strong individualized signature and CD-associated signals that are maintained
- also in patients who normalized their fecal calprotectin. United European Gastroenterology Journal2021 396.
- 668 101 Morasso C, Truffi M, Vanna R, Albasini S, Mazzucchelli S, Colombo F, et al. Raman
- Analysis Reveals Biochemical Differences in Plasma of Crohn's Disease Patients. J Crohns Colitis
 2020;14:1572-80.

671 102 Gupta NK, Thaker AI, Kanuri N, Riehl TE, Rowley CW, Stenson WF, et al. Serum analysis

of tryptophan catabolism pathway: correlation with Crohn's disease activity. Inflamm Bowel Dis2012;18:1214-20.

103 Nikolaus S, Schulte B, Al-Massad N, Thieme F, Schulte DM, Bethge J, *et al.* Increased
Tryptophan Metabolism Is Associated With Activity of Inflammatory Bowel Diseases.
Gastroenterology 2017;153:1504-16 e2.

677 104 Conrad M, Bittinger, K., Ren, Y., Dawany, N., Baldassano, R., Bushman, F., & Kelsen, J.

678 Taxonomic and metabolic differences among very early onset inflammatory bowel disease, older

679 onset pediatric inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition680 2018:S197-S8.

- 681 105 Gnewuch C, Liebisch G, Langmann T, Dieplinger B, Mueller T, Haltmayer M, *et al.* Serum 682 bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in 683 inflammatory bowel disease. World J Gastroenterol 2009;**15**:3134-41.
- 684 106 Jacobs JP, Goudarzi M, Singh N, Tong M, McHardy IH, Ruegger P, et al. A Disease-
- Associated Microbial and Metabolomics State in Relatives of Pediatric Inflammatory Bowel
 Disease Patients. Cell Mol Gastroenterol Hepatol 2016;2:750-66.
- 687 107 Weng YJ, Gan HY, Li X, Huang Y, Li ZC, Deng HM, *et al.* Correlation of diet, microbiota
 688 and metabolite networks in inflammatory bowel disease. J Dig Dis 2019;**20**:447-59.
- Sun R, Jiang J, Yang L, Chen L, Chen H. Alterations of Serum Bile Acid Profile in Patients
 with Crohn's Disease. Gastroenterol Res Pract 2022;2022:1680008.
- 691 109 Feng L, Zhou N, Li Z, Fu D, Guo Y, Gao X, *et al.* Co-occurrence of gut microbiota
 692 dysbiosis and bile acid metabolism alteration is associated with psychological disorders in Crohn's
 693 disease. FASEB J 2022;36:e22100.
- Ju J, Zhang C, Yang J, Yang Q, Yin P, Sun X. Deoxycholic acid exacerbates intestinal
 inflammation by modulating interleukin-1beta expression and tuft cell proportion in dextran
 sulfate sodium-induced murine colitis. PeerJ 2023;11:e14842.
- Kiasat A, Prast-Nielsen S, Rautiainen S, Engstrand L, Andersson F, Lindberg J, *et al.*Plasma bile acids in association with Crohn's disease. Scand J Gastroenterol 2024;**59**:674-82.
- Lu X, Zhou, M., Qu, C., Ge, W., Chen, Y. Serum Bile Acid Profile in Patients with
 Inflammatory Bowel Disease. Chinese Journal of Gastroenterology 2017;22.
- 113 Ma R, Zhu Y, Li X, Hu S, Zheng D, Xiong S, *et al.* A Novel Serum Metabolomic Panel for the Diagnosis of Crohn's Disease. Inflamm Bowel Dis 2023;**29**:1524-35.
- 114 Murakami M, Iwamoto J, Honda A, Tsuji T, Tamamushi M, Ueda H, *et al.* Detection of
 Gut Dysbiosis due to Reduced Clostridium Subcluster XIVa Using the Fecal or Serum Bile Acid
- 705 Profile. Inflamm Bowel Dis 2018;**24**:1035-44.
- Liu H, Xu M, He Q, Wei P, Ke M, Liu S. Untargeted serum metabolomics reveals specific
 metabolite abnormalities in patients with Crohn's disease. Front Med (Lausanne) 2022;9:814839.
- 116 Rieder F, Kurada S, Grove D, Cikach F, Lopez R, Patel N, et al. A Distinct Colon-Derived
- Breath Metabolome is Associated with Inflammatory Bowel Disease, but not its Complications.
 Clin Transl Gastroenterol 2016;7:e201.
- 117 Kurada S, Grove, D., Alkhouri, N., Lopez, R., Brzezinski, A., Baker, M., Fiocchi, C.,
 712 Dweik, R., & Rieder, F. A specific breath metabolome signature identifies patients with
- 713 inflammatory bowel diseases. American Journal of Gastroenterology 2015 S783.
- 714 118 Hicks L, Walker, D., Eng, D., Jiminez, B., Kinross, J., Holmes, E., Williams, H., &
- 715 Orchard, T. Urinary metabolic profiling of inflammatory bowel disease in a South Asian cohort
- 716 Journal of Crohn's and Colitis 2013:S258-S9.

Williams HR, Cox IJ, Walker DG, Cobbold JF, Taylor-Robinson SD, Marshall SE, et al. Differences in gut microbial metabolism are responsible for reduced hippurate synthesis in Crohn's disease. BMC Gastroenterol 2010;10:108. Bodelier AG, Smolinska A, Baranska A, Dallinga JW, Mujagic Z, Vanhees K, et al. Volatile Organic Compounds in Exhaled Air as Novel Marker for Disease Activity in Crohn's Disease: A Metabolomic Approach. Inflamm Bowel Dis 2015;21:1776-85. Hrdlicka L, Dryahina, K., Spanel, P., Bortlik, M., Duricova, D., Machkova, N., & Lukas, M. . Noninvasive quantification of volatile metabolites in breath: A potential indicator of inflammatory bowel diseases activity. . Gastroenterology 2012:S784. Dryahina K, Spanel P, Pospisilova V, Sovova K, Hrdlicka L, Machkova N, et al. Quantification of pentane in exhaled breath, a potential biomarker of bowel disease, using selected ion flow tube mass spectrometry. Rapid Commun Mass Spectrom 2013;27:1983-92. Wendland BE, Aghdassi E, Tam C, Carrrier J, Steinhart AH, Wolman SL, et al. Lipid peroxidation and plasma antioxidant micronutrients in Crohn disease. Am J Clin Nutr 2001;74:259-64. Ludek H. Pentane and carbon disulphide breath concentrations: A potential indicator of inflammatory bowel diseases activity. Journal of Gastrointestinal and Liver Diseases 2012: 21.



763 Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)

803 Table 1. Relative concentrations of fatty acids and annotated lipid metabolites in CD compared to non-CD controls

804

Lipids	Colonic Tissue	Stool	Serum and/or Plasma	Urine	Breath
Acetic Acid/acetate [48, 50,		1	14	1	^
51, 52, 53, 54]		V	↓ *↓ *	*	
Propionate [52, 55, 56, 57]		↑↓↑↓			
Butyrate/Butyric acid [50, 51, 52, 53, 55, 56, 57, 58, 59, 60]		$\downarrow \downarrow \uparrow \uparrow \uparrow \uparrow \uparrow \uparrow$			↑
Valerate/Pentanoic acid [56, 57, 58]		↑↓↑			
Hydroxyvalerate [13, 54, 61]	\downarrow			↑↓	
2-hydroxybutyrate [48, 61, 62, 63]			$\uparrow \uparrow \uparrow \uparrow \uparrow$		
Stearic acid [64, 65, 66]		1	$\downarrow\downarrow$		
Docosanoic acid [67, 68]			$\downarrow\downarrow$		
Oleic acid [62, 66, 68, 69, 70]		\downarrow	$\uparrow \uparrow \uparrow \uparrow \uparrow$		
Palmitoleic acid [62, 69, 71,			$\uparrow\uparrow\uparrow\uparrow$		
72]					
Alpha-Linolenic acid [64, 65, 69, 73, 74]			↓↑↑↓↓		
Eicosapentaenoic acid [67, 69, 73]	↓*		↓*↓↓		
Docosopentanoic acid [17, 69, 72, 73]			$\downarrow\downarrow\downarrow\downarrow\downarrow\downarrow$		
Docosahexaenoic Acid [64, 67, 68, 69, 72, 73, 74, 75]			↓↓↓↓↓↓↑		
Linoleic Acid [13, 62, 65, 66]	\downarrow	1	$\uparrow \uparrow$		
Arachidonic Acid [57, 66, 67, 68, 69, 70, 74, 76, 77, 78]		$\uparrow \uparrow$	↓↓↓↓↓↓↓		
Sphingolipids and ceramides [12, 13, 79, 80, 81, 82]	↑↑↓	↑	↑ * ↑ *↑		
Phosphatidylcholine [12, 79, 82, 83]	↑ ↑	↑	\downarrow		
Phosphatidylethanolamine [80, 82]	1		↑		
Phosphatidylserine [82, 84, 85]	1		↑↓		
Lysophosphatidylcholine [13, 62, 82, 84]	↑↓		↓↑		
Triacylglycerol [75, 79]		↓	↑	1	

⁸⁰⁵

⁸⁰⁶ 1: Each arrow represents a single study; directionality of the arrow denotes that the relative level of each

metabolite was either elevated (\uparrow) or decreased (\downarrow) in CD patients compared to non-IBD controls. ' \uparrow *' or 807 808 ψ *' represent the same study with multiple biological samples.

809	Table 2. Relative	concentrations of	f biogenic	amines and	l peptides in	CD compared t	o non-CD
-----	-------------------	-------------------	------------	------------	---------------	---------------	----------

810

controls					
Biogenic Amines and Peptides	Colonic Tissue	Stool	Serum and/or Plasma	Urine	Breath
Alanine [53, 54, 55, 62, 86, 87, 88, 89, 90, 91]		$\uparrow \uparrow \uparrow \uparrow \uparrow$	↓↓↓↑	$\downarrow\downarrow$	
Arginine [12, 48, 92, 93, 94]	1		↑ * ↑ *↑↓	\downarrow	
Asymmetric dimethyl arginine [93, 95]			$\uparrow\uparrow$		
Aspartic Acid [63, 89]			↑↓		
Carnitine [48, 57, 92]		↑	\downarrow	1	
Creatine [13, 48, 57, 61, 62]	\downarrow	1	↑ ↑↑		
Glutamine [13, 48, 61, 86, 91, 96, 97]	$\uparrow\uparrow$		$\downarrow \downarrow \downarrow \downarrow \downarrow \downarrow$		
Glutamic acid [61, 63]			↓↑		
Glutathione [75, 96]	1		1		
Glycine [48, 55, 61, 91, 98]		1	↑↓↑	1	
Di-methyl glycine [54, 89, 93]			1	$\downarrow\downarrow$	
Histidine[61, 62, 88, 91, 99, 100]		↑↑	↓↑↓↑		
Methyl-histidine [48, 61, 98]			↓*	↓*↑↓	
Indole [59, 79]		↑↓			
Isoleucine [46, 48, 53, 77, 87]		1	↓↑↑↑*↑*		
Leucine [53, 61, 92, 97]		↑	$\downarrow \downarrow \downarrow$		
Lysine [12, 48, 53, 55, 86, 92]	1	↑↑	$\downarrow \downarrow \downarrow \downarrow \downarrow$		
Methionine[12, 13, 61, 62, 63, 91]	$\uparrow\uparrow$		↑↓↓↑		
Ornithine [48, 61, 76, 88]		\downarrow	$\downarrow\downarrow$	↑	
Phenylalanine [12, 55, 66, 74, 97, 99, 101]	↑	$\uparrow\uparrow\uparrow$	$\downarrow\downarrow\downarrow\downarrow$		
Proline [12, 46, 48, 61, 62, 91]	1		↑↑↓↑↑		
Tryptophan [66, 88, 91, 93, 99, 101, 102, 103]		↑↑↑	↓↓↑↓↓		
Tyrosine [12, 48, 55, 61, 62, 66, 76, 90, 97]	↑	↓↑↑↑	$\downarrow\downarrow\downarrow\downarrow\downarrow\downarrow$		
Threonine [12, 48, 62]	↑		↓	↑	
Valine [48, 53, 61, 62, 77, 92]		1	$\uparrow \downarrow \downarrow \downarrow \downarrow \downarrow * \downarrow *$		
Citrulline [12, 62, 88, 93, 94]	↑	↑	↑↑↓		

811

812 1: Each arrow represents a single study; directionality of the arrow denotes that the relative level of each

813 metabolite was either elevated (\uparrow) or decreased (\downarrow) in CD patients compared to non-IBD controls. ' \uparrow *' or 814 ' \downarrow *' represent the same study with multiple biological samples.

816	Table 3. Relative concentrations of bile acids and in CD compared to non-CD controls
-----	--------------------------------------------------------------------------------------

Bile Acids	Colonic Tissue	Stool	Serum and/or Plasma	Urine	Breath
Chenodeoxycholate [57, 79, 104, 105, 106, 107]		$\uparrow \uparrow \uparrow \uparrow \uparrow$	$\downarrow\uparrow$		
Tauro-chenodeoxycholic acid [105, 108]			$\downarrow\downarrow$		
Glycochenodeoxycholate [57, 105, 108]		1	$\downarrow\downarrow$		
Cholate [57, 79, 105, 106, 109]		$\uparrow\uparrow\uparrow\uparrow$	↑		
Taurocholate [57, 66, 108]		↑ ↑	\rightarrow		
Glycocholate [57, 66, 105, 108]		↑↑	$\downarrow\downarrow$		
Lithocholate [57, 105, 108, 109, 110, 111, 112]		↓↓∗↓#	↓*↓#↓↓↓↓		
Isolithocholic acid [110, 113]		\downarrow	\rightarrow		
Deoxycholate [17, 57, 108, 109, 110, 111, 114]		↓∢↓#↓∗	↓*↓#↓◆↓↑↓↓		
Taurolithocholic acid [105, 110, 111]			$\downarrow\downarrow\downarrow\downarrow$		
Taurodeoxycholic acid [17, 105, 108, 109, 110, 111, 113]			$\downarrow \downarrow \downarrow \downarrow \downarrow \downarrow \downarrow \downarrow \downarrow \downarrow \downarrow$		
Glycolithocholic acid [105, 108, 109, 110, 111, 113]			$\downarrow\downarrow\downarrow\downarrow\downarrow\downarrow\downarrow\downarrow\downarrow$		
Glycodeoxycholic acid [105, 108, 109, 110, 111, 115]			$\downarrow \downarrow \downarrow \downarrow \downarrow \downarrow \downarrow \downarrow$		
Ursodeoxycholic acid [105, 109, 110]			↑↓↓		
Glycoursodeoxycholate [57, 105]		↑	\downarrow		
Tauroursodeoxycholic acid [105, 111]			$\downarrow \downarrow$		

 \uparrow : Each arrow represents a single study; directionality of the arrow denotes that the relative level of each 820 metabolite was either elevated (\uparrow) or decreased (\downarrow) in CD patients compared to non-IBD controls. ' $\uparrow*/\downarrow*$ ', 821 ' $\uparrow \bullet/ \downarrow \bullet$ ' and ' $\uparrow \#/ \downarrow \#$ ' represent the same study with multiple biological samples.

Table 4. Relative concentrations of other primary metabolites in CD compared to non-CD

- controls

OtherPrimaryMetabolites	Colonic Tissue	Stool	Serum and/or Plasma	Urine	Breath
Alpha-ketoglutarate [63, 92]			$\downarrow\downarrow$		
Ethanol [86, 116, 117]			↑		↑ ↑
Methanol [48, 61]			^∗	↓↓*	
Formic acid/Formate [61, 98, 118]			1	↑ ↑	
Galactose [48, 63]			↑	↑	
Hippuric acid/Hippurate [48, 54, 61, 89, 98, 118, 119]				↓↓↓↓↓↓↑	
Succinate[13, 48, 61, 90, 91, 92, 118]	\downarrow	1	↑↑↓	$\downarrow\downarrow$	
Citric acid/citrate [48, 54, 61, 62, 63, 89, 92, 97, 98]			↓↑↓↑↓∗	↓↓↓↓↓*	
Lactic acid/lactate [48, 61, 90, 97]		↑	↓↓↑		
Pyruvic acid/Pyruvate [61, 97, 113]		1	↓↑∗	↑ *	
Xylose [48, 63]			1	1	
Glucose [48, 61, 63, 97]			$\uparrow \uparrow \uparrow \uparrow \uparrow$		
Isoprene[51, 116, 120]					↓↑↑
Acetone[61, 120, 121]			↑		↓↑
Pentane [51, 121, 122, 123, 124]					

1: Each arrow represents a single study; directionality of the arrow denotes that the relative level of each

metabolite was either elevated (\uparrow) or decreased (\downarrow) in CD patients compared to non-IBD controls. ' \uparrow *' or ψ *' represent the same study with multiple biological samples.